Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Diabetes Obes Metab (2016) 18(4):31732
The New Phase 3 Numbers Here is the new July 23 data in plain language: TRIUMPH-2: 20.8% average weight loss at 80 weeks with 12 mg, plus A1C reductions up to 1.6 percentage points TRIUMPH-3: 22.6% average weight loss at 80 weeks with 12 mg The most common adverse events were gastrointestinal and generally mild to moderate Lilly plans to submit its BLA to the FDA in Q1 2027 The TRIUMPH-2 population had obesity or overweight plus type 2 diabetes, which makes the weight-loss result especially relevant because it came in a harder-to-treat metabolic group
Most of the product licences, or marketing authorities as they are called in the UK, for hydroxocobalamin date from the 1990s when the requirement for evidence was different than it is now
Dose Adjustment: Currently, 1.75 mg is the standard dose
